SPY397.37+3.48 0.88%
DIA321.28+1.89 0.59%
IXIC11,434.74+170.29 1.51%

BRIEF-Ideaya Biosciences Receives Orphan Drug Designation For Darovasertib

reuters.com · 05/02/2022 06:25
BRIEF-Ideaya Biosciences Receives Orphan Drug Designation For Darovasertib

- IDEAYA Biosciences Inc IDYA:

  • IDEAYA BIOSCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR DAROVASERTIB, A PKC INHIBITOR, FOR THE TREATMENT OF UVEAL MELANOMA

  • IDEAYA BIOSCIENCES-TARGETING DATA UPDATE FOR DAROVASERTIB AND CRIZOTINIB COMBINATION AND FDA GUIDANCE FOR REGISTRATION-ENABLING TRIAL DESIGN IN MID-2022

  • IDEAYA BIOSCIENCES -DAROVASERTIB DESIGNATION ENTITLING CO TO SOME TAX CREDITS, EXEMPTION FROM USER FEES, POTENTIAL STATUTORY MARKETING EXCLUSIVITY

Source text for Eikon: ID:nPnbG8NgFa

Further company coverage: IDYA


((reuters.briefs@thomsonreuters.com;))